InsidersTradesSigma
Track the Theravance Biopharma, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Theravance Biopharma, Inc. has published 214 reports. Market capitalisation: €885.2m. The latest transaction was disclosed on 24 August 2026 (Retenue fiscale). Among the most active insiders: Farnum Rhonda. Every trade is accessible without an account.
214
Insider Decl.
n/a
Thresholds
€15m
2 ops.
Buy Volume
€3m
32 ops.
Sell Volume
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 153 of 29,063 companies
89.4
score / 100
Value89
Quality90
FCF yld27%
Earn yld12%
EV/EBITDA6.9x
ROE21%
Gross mgn·
Net mgn99%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations214 total
5,667 shares@ US$16.950.011% mcap3.3% of flowOrdinary SharesSEC:0001898490-26-000012:0
7,952 shares@ US$16.950.015% mcap6.3% of flowOrdinary SharesSEC:0001966698-26-000008:0
6,258 shares@ US$16.950.012% mcap9.7% of flowOrdinary SharesSEC:0002012524-26-000008:0
8,112 shares@ US$16.950.016% mcap6.9% of flowOrdinary SharesSEC:0001961289-26-000008:0
20,034 shares@ US$16.950.038% mcap6.1% of flowOrdinary SharesSEC:0001302443-26-000012:0
5,564 shares@ US$17.17120.011% mcap0.5% of flowCOMSEC:0001877589-26-000002:1
1,400 shares@ US$17.040.0027% mcap0.1% of flowCOMSEC:0001877589-26-000002:0
6,009 sharesOrdinary SharesSEC:0001833453-26-000006:0
13,314 shares@ US$16.38630.024% mcap100.0% of flowCommonSEC144:0001950047-26-006154
18,750 shares0Ordinary SharesSEC:0001898490-26-000006:0
37,500 shares0Ordinary SharesSEC:0001966698-26-000004:0
37,500 shares0Ordinary SharesSEC:0001961289-26-000004:0
75,000 shares0Ordinary SharesSEC:0001302443-26-000004:0
7,767 shares@ US$13.91635.3% of flowOrdinary SharesSEC:0001898490-26-000004:0
16,851 shares@ US$19.6633.1% of flowOrdinary SharesSEC:0002012524-26-000002:0
20,833 shares@ US$19.6620.2% of flowOrdinary SharesSEC:0001966698-26-000002:0
13,929 shares@ US$19.669.8% of flowOrdinary SharesSEC:0001898490-26-000002:0
74,975 shares@ US$19.6627.8% of flowOrdinary SharesSEC:0001302443-26-000002:0
20,672 shares@ US$19.6621.8% of flowOrdinary SharesSEC:0001961289-26-000002:0
7,767 shares@ US$18.74995.8% of flowOrdinary SharesSEC:0001898490-25-000008:0
14,000 shares@ US$20.000.029% mcap50.0% of flowOrdinary SharesSEC:0001256230-25-000009:0
6,989 shares@ US$17.9019.1% of flowOrdinary SharesSEC:0002012524-25-000006:0
19,024 shares@ US$17.9021.5% of flowOrdinary SharesSEC:0001966698-25-000006:0
18,627 shares@ US$17.9023.3% of flowOrdinary SharesSEC:0001961289-25-000006:0
9,060 shares@ US$17.907.0% of flowOrdinary SharesSEC:0001898490-25-000006:0
25 of 214 declarations
关于 Theravance Biopharma, Inc.
Theravance Biopharma, Inc. 是一家在美国纳斯达克上市的生物制药公司，股票代码为TBPH。公司运营分为两部分，分别位于美国南旧金山、加利福尼亚州和爱尔兰都柏林。2014年6月2日，公司从Theravance, Inc.分拆后，成为一家独立的上市公司。公司的使命是开发和商业化差异化药物，特别侧重于专科呼吸系统疾病。([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-inc-and-theravance-biopharma-inc-announce-completion?utm_source=openai)) Theravance Biopharma的商业模式已逐渐从广泛的研发型生物技术公司转向专注于精简产品组合的公司。其商业支柱是YUPELRI® (revefenacin) 吸入溶液，这是一种经FDA批准的慢性阻塞性肺病（COPD）维持治疗药物。公司强调其在呼吸系统疾病领域数十年的专业知识，并以“创造不同药物”为定位，其价值创造既来自于已上市产品，也来自于选择性的管线选择权。([theravance.com](https://www.theravance.com/about-us/our-company/?utm_source=openai)) 在竞争方面，TBPH最好被视为一家专业的SME生物技术公司，而非多元化的制药平台。这种专业化使管理层能够将资本和运营注意力集中在一系列狭窄的治疗机会上，公司相信可以在这些领域建立持久的价值。公司还依赖合作结构和共享商业化经济效益，特别是与Viatris在美国合作推广YUPELRI，这减轻了从头建立一个完全整合的销售组织的负担。([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-third-quarter-2025-financial?utm_source=openai)) 近期发展对投资案例尤为重要。2026年3月，Theravance Biopharma公布了2025年第四季度和全年业绩，报告非GAAP盈利能力再创纪录，YUPELRI品牌层面盈利能力创纪录，资产负债表得到加强。与此同时，公司的ampreloxetine项目成为关键的临床催化剂：关键的CYPRESS III期研究于2025年完成入组，但2026年3月公布的顶线结果显示该研究未达到主要终点。在此结果之后，董事会加快了战略审查，公司宣布了成本削减措施。管理层已表示将更专注于最大化YUPELRI的价值并保持财务灵活性。([investor.theravance.com](https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-8?utm_source=openai)) 对于投资者而言，Theravance Biopharma仍然是美国纳斯达克上市的一家专业医疗保健公司，结合了商业呼吸系统资产与剩余管线和战略审查选择权。该股票的特点反映了生物技术执行风险以及通过严格的资本配置和公司行动实现价值的潜力。
